Helixmith Co., Ltd (KOSDAQ:084990)
 5,320.00
 +320.00 (6.40%)
  Oct 31, 2025, 1:40 PM KST
Helixmith Revenue
Helixmith had revenue of 612.74M KRW in the quarter ending June 30, 2025, a decrease of -14.95%. This brings the company's revenue in the last twelve months to 4.98B, up 57.12% year-over-year. In the year 2024, Helixmith had annual revenue of 4.97B with 18.38% growth.
Revenue (ttm) 
 4.98B
Revenue Growth 
 +57.12%
P/S Ratio 
 46.24
Revenue / Employee 
 85.85M
Employees 
 58
Market Cap 
230.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 4.97B | 772.35M | 18.38% | 
| Dec 31, 2023 | 4.20B | 1.40B | 50.08% | 
| Dec 31, 2022 | 2.80B | 483.36M | 20.87% | 
| Dec 31, 2021 | 2.32B | -1.93B | -45.48% | 
| Dec 31, 2020 | 4.25B | -206.22M | -4.63% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Biologics | 5.03T | 
| Celltrion | 3.75T | 
| Yuhan | 2.17T | 
| SK Biopharmaceuticals | 620.28B | 
| PharmaResearch | 449.81B | 
| Sam Chun Dang Pharm. | 215.10B | 
| ALTEOGEN | 158.06B | 
| LigaChem Biosciences | 148.28B | 
Helixmith News
- 7 months ago - P/E Ratio Insights for Vipshop Holdings - Benzinga
- 1 year ago - Price Over Earnings Overview: Vipshop Holdings - Benzinga